Siemens Fonds Invest GmbH Boosts Holdings in Cencora, Inc. (NYSE:COR)

Siemens Fonds Invest GmbH boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 944.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,972 shares of the company’s stock after buying an additional 18,060 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in Cencora were worth $4,645,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Miracle Mile Advisors LLC purchased a new stake in shares of Cencora in the 4th quarter worth $273,000. Signal Advisors Wealth LLC grew its holdings in Cencora by 19.5% during the fourth quarter. Signal Advisors Wealth LLC now owns 1,831 shares of the company’s stock valued at $411,000 after purchasing an additional 299 shares during the period. Oak Thistle LLC purchased a new stake in Cencora in the fourth quarter worth about $455,000. Fifth Third Wealth Advisors LLC raised its stake in shares of Cencora by 11.8% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 1,958 shares of the company’s stock worth $440,000 after buying an additional 206 shares during the period. Finally, Kathmere Capital Management LLC lifted its position in shares of Cencora by 14.6% during the 4th quarter. Kathmere Capital Management LLC now owns 2,091 shares of the company’s stock valued at $470,000 after buying an additional 266 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 2.3%

Shares of Cencora stock opened at $285.51 on Friday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $309.35. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a 50-day moving average price of $278.51 and a 200-day moving average price of $254.58. The firm has a market cap of $55.37 billion, a price-to-earnings ratio of 40.61, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analysts’ expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $3.80 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, May 16th. Cencora’s dividend payout ratio is 25.52%.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares of the company’s stock, valued at approximately $3,934,326.20. The trade was a 21.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on COR shares. Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Bank of America lifted their target price on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Finally, JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $301.18.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.